/
/
Clinical Trial: Avelumab in Combination With Hypofractionated Radiotherapy in Patients With Relapsed Refractory Multiple Myeloma
Clinical Trial: Avelumab in Combination With Hypofractionated Radiotherapy in Patients With Relapsed Refractory Multiple Myeloma image
Clinical Trial: Avelumab in Combination With Hypofractionated Radiotherapy in Patients With Relapsed Refractory Multiple Myeloma
Posted Jun 28, 2019

This open-label, Phase 2 study is studying whether the monoclonal antibody Avelumab, in combination with radiation therapy, is safe in the treatment of relapsed/refractory myeloma.

  • Open-Label: Patients and their doctors will know both the treatment and the dose that they will be receiving.

One of the ways that cancer cells have learned to protect themselves is by using special proteins that block our immune system from detecting and attacking them. Avelumab works by blocking the cancer’s protective protein (PD-L1), which helps our immune system to target and destroy any cancer cells it finds. Avelumab is currently FDA approved for use in Merkel-Cell Carcinoma (a type of skin cancer), but researchers are hopeful that it can be helpful in treating myeloma.

In this trial, Avelumab will be used concurrently with radiation therapy, so in order to be eligible, patients must have at least one plasmacytoma or lytic lesion that would be appropriate to treat with radiation therapy. This trial will be organized into 28 day cycles, and all patients who join this trial will receive the same regimen. Patients will receive Avelumab through an intravenous infusion every two weeks (on cycle days 1 and 15). After two doses of Avelumab (one cycle), patients will then receive five radiation therapy treatments on consecutive days. Patients may then continue to receive Avelumab every two weeks indefinitely, as long as they don’t develop bad side effects and their myeloma doesn’t get worse.

Patients will be monitored for overall response, development of side effects, and duration of response. Patients must have relapsed/refractory myeloma, and adequate bone marrow, liver, and kidney function to participate. Researchers are seeking 30 participants, and the study is scheduled to open in May 2019 at the National Institutes of Health in Bethesda, MD.

Click the link below to view full inclusion/exclusion criteria, and to learn more about this trial. You can also call SparkCures with any questions at (888) 828-2206.

 

Check your eligibility for this trial through your Healthtree Profile.

 

Learn more about this trial with SparkCures.

 

The author Erika Johnson

about the author
Erika Johnson

Myeloma Crowd Editorial Contributor, Nursing student, and cancer advocate.

More Myeloma Clinical Trials Articles

Get the latest thought leadership on Myeloma delivered straight to your inbox.

Subscribe to the weekly "HealthTree Community for Myeloma Newsletter" for Myeloma news, life with Myeloma stories, Myeloma clinical trials, Myeloma 101 articles and events with Myeloma experts.

Thanks to our HealthTree Community for Myeloma Sponsors:

Genentech
Abbvie
Bristol Myers Squibb
Janssen Oncology
GSK

Follow Us

facebook instagram twitter youtube

Copyright © 2022 HealthTree Foundation. All Rights Reserved.

The HealthTree Foundation / Myeloma Crowd is a qualified 501(c)(3) tax-exempt organization. Tax ID 45-5354811

 https://www.guidestar.org/profile/45-5354811